Drug Profile
Research programme: cancer vaccines - Sapvax
Alternative Names: SV-283; SV-638Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator University of Auckland
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lymphoma; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Malignant melanoma in New Zealand (Parenteral)
- 23 Aug 2023 Discontinued - Preclinical for Non-small cell lung cancer in New Zealand (Parenteral)
- 23 Aug 2023 Discontinued - Preclinical for Ovarian cancer in New Zealand (Parenteral)